These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22745437)

  • 1. AAV-directed persistent expression of a gene encoding anti-nicotine antibody for smoking cessation.
    Hicks MJ; Rosenberg JB; De BP; Pagovich OE; Young CN; Qiu JP; Kaminsky SM; Hackett NR; Worgall S; Janda KD; Davisson RL; Crystal RG
    Sci Transl Med; 2012 Jun; 4(140):140ra87. PubMed ID: 22745437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AAVrh.10-mediated expression of an anti-cocaine antibody mediates persistent passive immunization that suppresses cocaine-induced behavior.
    Rosenberg JB; Hicks MJ; De BP; Pagovich O; Frenk E; Janda KD; Wee S; Koob GF; Hackett NR; Kaminsky SM; Worgall S; Tignor N; Mezey JG; Crystal RG
    Hum Gene Ther; 2012 May; 23(5):451-9. PubMed ID: 22486244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors.
    Watanabe M; Boyer JL; Crystal RG
    Gene Ther; 2010 Aug; 17(8):1042-51. PubMed ID: 20596059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid/sustained anti-anthrax passive immunity mediated by co-administration of Ad/AAV.
    De BP; Hackett NR; Crystal RG; Boyer JL
    Mol Ther; 2008 Jan; 16(1):203-9. PubMed ID: 18059375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV.
    Skaricic D; Traube C; De B; Joh J; Boyer J; Crystal RG; Worgall S
    Virology; 2008 Aug; 378(1):79-85. PubMed ID: 18556039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined active and passive immunization against nicotine: minimizing monoclonal antibody requirements using a target antibody concentration strategy.
    Cornish KE; Harris AC; LeSage MG; Keyler DE; Burroughs D; Earley C; Pentel PR
    Int Immunopharmacol; 2011 Nov; 11(11):1809-15. PubMed ID: 21802529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Development and Characterization of an scFv-Fc Fusion-Based Gene Therapy to Reduce the Psychostimulant Effects of Methamphetamine Abuse.
    Hay CE; Ewing LE; Hambuchen MD; Zintner SM; Small JC; Bolden CT; Fantegrossi WE; Margaritis P; Owens SM; Peterson EC
    J Pharmacol Exp Ther; 2020 Jul; 374(1):16-23. PubMed ID: 32245884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice.
    Liu W; Zhao L; Blackman B; Parmar M; Wong MY; Woo T; Yu F; Chiuchiolo MJ; Sondhi D; Kaminsky SM; Crystal RG; Paul SM
    J Neurosci; 2016 Dec; 36(49):12425-12435. PubMed ID: 27927959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic vaccines for nicotine dependence.
    Maurer P; Bachmann MF
    Curr Opin Mol Ther; 2006 Feb; 8(1):11-6. PubMed ID: 16506520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-hIgE gene therapy of peanut-induced anaphylaxis in a humanized murine model of peanut allergy.
    Pagovich OE; Wang B; Chiuchiolo MJ; Kaminsky SM; Sondhi D; Jose CL; Price CC; Brooks SF; Mezey JG; Crystal RG
    J Allergy Clin Immunol; 2016 Dec; 138(6):1652-1662.e7. PubMed ID: 27372563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transfer.
    Wang G; Qiu J; Wang R; Krause A; Boyer JL; Hackett NR; Crystal RG
    Cancer Gene Ther; 2010 Aug; 17(8):559-70. PubMed ID: 20448672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Anti-Nicotine Vaccine Using a Trimeric Coiled-Coil Hapten Carrier.
    Miller KD; Roque R; Clegg CH
    PLoS One; 2014; 9(12):e114366. PubMed ID: 25494044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses.
    De BP; Heguy A; Hackett NR; Ferris B; Leopold PL; Lee J; Pierre L; Gao G; Wilson JM; Crystal RG
    Mol Ther; 2006 Jan; 13(1):67-76. PubMed ID: 16260185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mediators of the effect of nicotine pre-treatment on quitting smoking.
    Hajek P; Lewis S; Munafo M; Lindson N; Coleman T; Aveyard P;
    Addiction; 2018 Dec; 113(12):2280-2289. PubMed ID: 30066385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine.
    Rosenberg JB; De BP; Hicks MJ; Janda KD; Kaminsky SM; Worgall S; Crystal RG
    Hum Gene Ther; 2013 Jun; 24(6):595-603. PubMed ID: 23611296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab.
    Mao Y; Kiss S; Boyer JL; Hackett NR; Qiu J; Carbone A; Mezey JG; Kaminsky SM; D'Amico DJ; Crystal RG
    Hum Gene Ther; 2011 Dec; 22(12):1525-35. PubMed ID: 21801028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New directions in nicotine vaccine design and use.
    Pentel PR; LeSage MG
    Adv Pharmacol; 2014; 69():553-80. PubMed ID: 24484987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent progress in vaccines against nicotine addiction].
    Wang GB; Zhu CJ
    Yao Xue Xue Bao; 2013 Aug; 48(8):1189-94. PubMed ID: 24187824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing immunogenicity of a 3'aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates.
    McCluskie MJ; Pryde DC; Gervais DP; Stead DR; Zhang N; Benoit M; Robertson K; Kim IJ; Tharmanathan T; Merson JR; Davis HL
    Int Immunopharmacol; 2013 May; 16(1):50-6. PubMed ID: 23562759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probing the protective effects of a conformationally constrained nicotine vaccine.
    Moreno AY; Azar MR; Koob GF; Janda KD
    Vaccine; 2012 Oct; 30(47):6665-70. PubMed ID: 22963803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.